File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.14218/JCTH.2022.00255
- Scopus: eid_2-s2.0-85141456204
- PMID: 36406319
- WOS: WOS:000859082700001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma
Title | Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma |
---|---|
Authors | |
Keywords | Cancer therapy Ferroptosis Hepatocellular carcinoma Molecular targets Sorafenib |
Issue Date | 28-Feb-2023 |
Publisher | XIA & HE Publishing Inc. |
Citation | Journal of Clinical and Translational Hepatology, 2023, v. 11, n. 1, p. 207-218 How to Cite? |
Abstract | Hepatocellular carcinoma (HCC) is one of the most common and highly heterogeneous malignancies worldwide. Despite the rapid development of multidisciplinary treatment and personalized precision medicine strategies, the overall survival of HCC patients remains poor. The limited survival benefit may be attributed to difficulty in early diagnosis, the high recurrence rate and high tumor heterogeneity. Ferroptosis, a novel mode of cell death driven by iron-dependent lipid peroxidation, has been implicated in the development and therapeutic response of various tumors, including HCC. In this review, we discuss the regulatory network of ferroptosis, describe the crosstalk between ferroptosis and HCC-related signaling pathways, and elucidate the potential role of ferroptosis in various treatment modalities for HCC, such as systemic therapy, radiotherapy, immunotherapy, interventional therapy and nanotherapy, and applications in the diagnosis and prognosis of HCC, to provide a theoretical basis for the diagnosis and treatment of HCC to effectively improve the survival of HCC patients. |
Persistent Identifier | http://hdl.handle.net/10722/331269 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.988 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huang, Z | - |
dc.contributor.author | Xia, H | - |
dc.contributor.author | Cui, Y | - |
dc.contributor.author | Yam, JWP | - |
dc.contributor.author | Xu, Y | - |
dc.date.accessioned | 2023-09-21T06:54:12Z | - |
dc.date.available | 2023-09-21T06:54:12Z | - |
dc.date.issued | 2023-02-28 | - |
dc.identifier.citation | Journal of Clinical and Translational Hepatology, 2023, v. 11, n. 1, p. 207-218 | - |
dc.identifier.issn | 2225-0719 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331269 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is one of the most common and highly heterogeneous malignancies worldwide. Despite the rapid development of multidisciplinary treatment and personalized precision medicine strategies, the overall survival of HCC patients remains poor. The limited survival benefit may be attributed to difficulty in early diagnosis, the high recurrence rate and high tumor heterogeneity. Ferroptosis, a novel mode of cell death driven by iron-dependent lipid peroxidation, has been implicated in the development and therapeutic response of various tumors, including HCC. In this review, we discuss the regulatory network of ferroptosis, describe the crosstalk between ferroptosis and HCC-related signaling pathways, and elucidate the potential role of ferroptosis in various treatment modalities for HCC, such as systemic therapy, radiotherapy, immunotherapy, interventional therapy and nanotherapy, and applications in the diagnosis and prognosis of HCC, to provide a theoretical basis for the diagnosis and treatment of HCC to effectively improve the survival of HCC patients. | - |
dc.language | eng | - |
dc.publisher | XIA & HE Publishing Inc. | - |
dc.relation.ispartof | Journal of Clinical and Translational Hepatology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Cancer therapy | - |
dc.subject | Ferroptosis | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Molecular targets | - |
dc.subject | Sorafenib | - |
dc.title | Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.14218/JCTH.2022.00255 | - |
dc.identifier.pmid | 36406319 | - |
dc.identifier.scopus | eid_2-s2.0-85141456204 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 207 | - |
dc.identifier.epage | 218 | - |
dc.identifier.isi | WOS:000859082700001 | - |
dc.identifier.issnl | 2225-0719 | - |